Syngeneic Mouse Models

Syngeneic mouse models represent one of the first steps needed to determine the efficacy of your novel immunotherapies in an in vivo model with functional immune system  

Home » Oncology CRO Services » Syngeneic Mouse Models

Syngeneic mouse models are established from immortalized murine cancer cells originating from inbred mouse strains that are implanted and grown in genetically identical strains. Avoiding the need to use immunocompromised mice, this approach allows you to study your novel immunotherapy’s efficacy in a mouse model that combines tumor microenvironment interactions with a fully functional immune system.  

Therefore, experts at InnoSer recommend the use of syngeneic rodent models (mice or rats) as a first step to evaluate the efficacy of your novel immunotherapy approaches (vaccines, mRNA-based therapeutics, immune checkpoint inhibitors, antibody-drug conjugates, (stem) cell therapy such as CAR-T cell therapy, NK cell therapy, etc., as well as classical anti-tumoral compounds (chemotherapy, radiotherapy). Accordingly, syngeneic mouse models represent an easy-to-use, relatively inexpensive mouse model with short study timelines (2-4 weeks), offering reproducible immune response results. However, for more advanced studies, InnoSer’s experts recommend working with humanized mouse models

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions most cost-effectively. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.  

Services with Syngeneic Mouse from InnoSer:  

  • Available as subcutaneous or orthotopic models (fluorescently labeled rodent cell lines or followed-up via ultrasound) 
  • Both murine and rat cell lines are available. 
  • Complementary immuno-oncology in vitro assays and PK/PD profiling services 

Find the right model for you.

Compare our model capabilities and discover which of our oncology platforms suits your research needs

oncology leaflet download

Key Readouts in Syngeneic Mouse Models:

Test the efficacy of your treatments using syngeneic mouse models with the following readouts:    

  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • In vivo imaging (bioluminescence imaging, ultrasound)  
  • Isolation of tumors and other relevant organs for histopathology analyses (biomarker analyses)  
  • Immune cell profiling (multi-panel flow cytometry analyses with up to 12 markers; lymphoid, myeloid panels) 
  • Blood sampling for biomarker analyses (MSD) 

    Example data featuring syngeneic mouse models:    

      Related model options

      Oncology Platform Overview

      Highly relevant oncology CRO services to facilitate preclinical drug development.

      Cell line-derived Xenograft (CDX) Mouse Models

      CDX models represent one of the first steps to evaluate the efficacy using in vivo models of human cancer.

      Patient-derived Xenograft (PDX) Mouse Models

      Recapitulate the tumor and patient heterogeneity using patient-derived xenograft (PDX) mouse models.

      AAALAC Accreditation

      InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

      AAALAC logo

      Animal Welfare

      The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

      Need more information?

      If you have any questions about how we can help accelerate your research,

      then let us know